🇺🇸 FDA
Pipeline program

Locametz 25 micrograms kit for radiopharmaceutical preparation, PIFLUFOLASTAT (18F), PIFLUFOLASTAT (18F), Pluvicto 1 000 MBq/mL solution for injection/infusion

CAAA617D12302

Phase 3 small_molecule active

Quick answer

Locametz 25 micrograms kit for radiopharmaceutical preparation, PIFLUFOLASTAT (18F), PIFLUFOLASTAT (18F), Pluvicto 1 000 MBq/mL solution for injection/infusion for Oligometastatic prostate cancer (OMPC) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Oligometastatic prostate cancer (OMPC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials